Actavis Finds A Settlement On Intuniv Antitrust Suit
Case Against Takeda’s Shire Continues
A settlement agreement between Actavis and Shire in 2013 over the originator’s Intuniv (guanfacine hydrochloride) treatment for attention-deficit hyperactivity disorder led both direct and indirect purchasers to file antitrust suits accusing the firms of unlawfully delaying generic competition. A settlement in the case with direct purchasers has now been reached.
